Fluctuations in attention: PD dementia vs DLB with parkinsonism

Neurology

Volumn 59, Issue 11, 2002, Pages 1714-1720

  Ballard, C G ^a,d   Aarsland, D ^b   McKeith, I ^a   O'Brien, J ^a   Gray, A ^a   Cormaak, F ^a   Burn, D ^a   Cassidy, T ^a   Starfeldt, R ^b   Larsen, J P ^b   Brown, R ^c   Tovee, M ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b Rogaland Psykiatriske Sjukehus   (Norway)

^c KING'S COLLEGE LONDON   (United Kingdom)

^d NEWCASTLE GENERAL HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AGED; ALERTNESS; ARTICLE; ATTENTION; CLINICAL FEATURE; COGNITION; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; FEMALE; HUMAN; LEWY BODY; MAJOR CLINICAL STUDY; MALE; PARKINSON DISEASE; PARKINSONISM; PRIORITY JOURNAL; REACTION TIME;

EID: 0037058789     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/01.WNL.0000036908.39696.FD     Document Type: Article

References (59)

1. Ouchi Y, Yoshikawa E, Okada H, et al. Alterations in binding site density of dopamine transporter in the striatum, orbitofrontal cortex, and amygdala in early Parkinson's disease: Compartment analysis for beta-CFT binding with positron emission tomography. Ann Neurol 1999;45:601-610.
2. Kuikka JT, Bergstrom KA, Vanninen E, et al. Initial experience with single-photon emission tomography using iodine-123-labelled 2 beta-carbomethoxy-3 beta-(4-iodophenyl) tropane in human brain. Eur J Nucl Med 1993;20:783-786.
3. Kuhl DE, Minoshima S, Fessler JA, et al. In vivo mapping of cholinergic terminals in normal aging, Alzheimer's disease, and Parkinson's disease. Ann Neurol 1996;40:399-410.
4. Lange KW, Wells FR, Jenner P, Marsden CD. Altered muscarinic and nicotinic receptor densities in cortical and subcortical brain regions in Parkinson's disease. J Neurochem 1993; 60:197-203.
5. Piggott MA, Marshall EF. Neurochemical correlations of pathological and iatrogenic extrapyramidal symptoms. In: Perry RH, McKeith IG, Perry EK, eds. Dementia with Lewy Bodies: Clinical, Pathological and Treatment Issues. Cambridge: Cambridge University Press, 1996;449-467.
6. Apaydin H, Ahlskog JE, Parisi JE, Boeve BF, Dickson DW. Parkinson's disease neuropathology: Later-developing dementia and loss of the levodopa response. Arch Neurol 2002;59: 102-112.
7. Muenter MD, Forno LS, Hornykiewicz O, et al. Hereditary form of parkinsonism-dementia. Ann Neurol 1998;43:768-781.
8. Gwinn-Hardy K, Mehta ND, Farrer M, et al. Distinctive neuropathology revealed by alpha-synuclein antibodies in hereditary parkinsonism and dementia linked to chromosome 4p. Acta Neuropathol 2000;99:663-672.
9. Marder K, Tang MX, Cote L, et al. The frequency and associated risk factors for dementia in patients with Parkinson's disease. Arch Neurol 1995;52:695-701.
10. Tison F, Dartigues JF, Auriacombe S, et al. Dementia in Parkinson's disease. A population-based study in ambulatory and institutionalized individuals. Neurology 1995;45:705-708.
11. Aarsland D, Larsen JP, Tandberg E. Frequency of dementia in Parkinson's disease. Arch Neurol 1996;53:538-542.
12. Louis ED, Marder K, Cote L, et al. Mortality from Parkinson's disease. Arch Neurol 1997;54:260-264.
13. McKeith IG, Galasko D, Kosaka K, et al. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): Report of the consortium on DLB international workshop. Neurology 1996;47:1113-1124.
14. Hansen L, Salmon D, Galasko D, et al. The Lewy body variant of Alzheimer's disease: A clinical & pathological entity. Neurology 1990;40:1-8.
15. Perry RH, Irving D, Blessed G, et al. A clinically & pathologically distinct form of Lewy body dementia in the elderly. J Neurol Sci 1990;95:119-139.
16. Dickson DW, Ruan D, Crystal H, et al. Hippocampal degeneration differentiates diffuse Lewy body disease (DLBD) from Alzheimer's disease: Light & electron microscopic immunocytochemistry of CA2-3 neurites specific to DLBD. Neurology 1991;41:1402-1409.
17. Ballard CG, Mohan RNC, Patel A, Bannister C. Idiopathic clouding of consciousness - Do the patients have cortical Lewy body disease? Int J Geriatr Psychiatry 1993;8:571-576.
18. Ballard CG, Saad K, Patel A, et al. The prevalence & phenomenology of psychotic symptoms in dementia sufferers. Int J Geriatr Psychiatry 1995;10:477-486.
19. Shergill S, Mullen E, D'Ath P, Katona C. What is the clinical prevalence of Lewy body dementia? Int J Psychiatry 1994;9: 907-912.
20. Walker MP, Ayre GA, Cummings JL, et al. The one day clinician assessment of fluctuation and the one day fluctuation assessment scale. Br J Psychiatry 2000;177:252-256.
21. Walker MP, Ayre GA, Cummings JL, et al. Quantifying fluctuation in dementia with Lewy bodies, Alzheimer's disease, and vascular dementia. Neurology 2000;54:1616-1625.
22. Kutukcu Y, Marks WJ Jr, Goodin DS, Aminoff MJ. Simple and choice reaction time in Parkinson's disease. Brain Res 1999;815:367-372.
23. Reikkinen M, Kejonen K, Jakala P, et al. Reduction of noradrenaline impairs attention and dopamine depletion slows responses in Parkinson's disease. Eur J Neurosci 1998;10: 1429-1435.
24. Blanchet S, Marie RM, Dauvillier F, et al. Cognitive processes involved in delayed non-matching to sample performance in Parkinson's disease. Eur J Neurol 2000;7:473-483.
25. Kutukcu Y, Marks WJ Jr, Goodin DS, Aminoff MJ. Cerebral accompaniments to simple and choice reaction time tasks in Parkinson's disease. Brain Res 1998;799:1-5.
26. Montgomery EB Jr, Nuessen J. The movement speed/accuracy operator in Parkinson's disease. Neurology 1990;40:269-272.
27. Montgomery EB Jr, Nuessen J, Gorman DS. Reaction time and movement velocity abnormalities in Parkinson's disease under different task conditions. Neurology 1991;41:1476-1481.
28. Maruyama T. Cognitive dysfunction in Parkinson's disease. Jpn J Clin Med 2000;58:2007-2015.
29. Hsieh S. The psychological refractory period in Parkinson's disease. Percept Mot Skills 2000;91:893-902.
30. Pinter MM, Birk M, Helscher RJ, Binder H. Short term effects of amantadine sulphate on motor performance and reaction time in patients with idiopathic Parkinson's disease. J Neurotansmission 1999;106:711-724.
31. Smith MC, Goldman WP, Janer KW, et al. Cognitive speed in nondemented Parkinson's disease. J Int Neuropsychol Soc 1998;4:584-592.
32. Berry EL, Nicolson RL, Foster JK, et al. Slowing of reaction time in Parkinson's disease: The involvement of the frontal lobes. Neuropsychologia 1999;37:787-795.
33. Muller T, Eising E, Kuhn W, et al. Delayed motor response correlates with striatal degradation in Parkinson's disease. Acta Neurol Scand 1999;100:227-230.
34. Gauntlett-Gilbert J, Brown VJ. Reaction time deficits and Parkinson's disease. Neurosci Biobehav Rev 1998;22:865-881.
35. Folstein MF, Folstein SE, McHugh PR. "Mini-Mental State". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-198.
36. McKeith IG, Ballard CG, Perry RH, et al. A prospective validation of the consensus criteria for the clinical diagnosis of dementia with Lewy bodies. Neurology 2000;54:1050-1058.
37. Ballard C, McKeith I, Burn D, et al. The UPDRS scale as a means of identifying extrapyramidal signs in patients suffering from dementia with Lewy bodies. Acta Neurol Scand 1997; 96:366-371.
38. Hoehn MH, Yahr MD. Parkinsonism. Onset, progression, and mortality. Neurology 1967;17:427-442.
39. Fahn S, Elton R. Unified Parkinson's Disease Rating Development Committee. Unified Parkinson's Disease Rating Scale. In: Fahn S, Marsden CD, Calne D, eds. Recent Developments in Parkinson's Disease. New York: Macmillan, 1987;153-163.
40. Devanand DP, Miller L, Richards M, et al. The Columbia University scale for psychopathology in Alzheimer's disease. Arch Neurol 1992;49:371-376.
41. Cummings JL, Mega M, Gray K, et al. The Neuropsychiatric Inventory: Comprehensive assessment of psychopathology in dementia. Neurology 1994;44:2308.
42. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: A clinicopathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992;55:181-184.
43. American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 3rd edition revised. Washington, DC: American Psychiatric Association, 1987.
44. Mattis S. Dementia rating scale. In: Bellak L, Karasu TB, eds. Geriatric Psychiatry. A Handbook for Psychiatrists and Primary Care Physicians. New York: Grune & Stratton, 1976; 108-121.
45. Thurstone LL, Mellinger J. The Stroop Test. No. 3. Chapel Hill, NC: The Psychometric Laboratory, University of North Carolina, 1953.
46. Benton AL. The Revised Visual Retention Test, 4th Ed. New York: Psychological Corporation, 1974.
47. Benton AL, Varney NR, Hamsher K deS. Visuospatial judgment: A clinical test. Arch Neurol 1978;35:364-367.
48. Roth M, Tym E, Mountjoy C, et al. CAMDEX: A standardised instrument for the diagnosis of mental disorder in the elderly with special reference to the early detection of dementia. Br J Psychiatry 1986;149:698-709.
49. Dewey ME, Copeland JRM, Lobo A, et al. Computerised diagnosis from a standardised history schedule: A preliminary communication about the organic section of the HAS-AGECAT system. Int J Geriatr Psychiatry 1992;7:443-446.
50. McKhann G, Drachman D, Folstein M, et al. Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Forces on Alzheimer's Disease. Neurology 1984;34:939-944.
51. Simpson PM, Surmon DJ, Wesnes KA, Wilcock GK. The cognitive drug research computerized assessment system for demented patients: A validation study. Int J Geriatr Psychiatry 1991;6:95-102.
52. SPSS. Statistical Package for the Social Sciences. Windows Version, Release 5.0. Chicago: SPSS, 1992.
53. Aarsland D, Karslen K. Neuropsychiatric aspects of Parkinson's disease. Curr Psychiatry Reports 1999;1:61-68.
54. Aarsland D, Laake K, Larsen JP, Janvin C. Donepezil treatment in Parkinson's disease with dementia: A double-blind, placebo-controlled crossover study. Neurology 2001;56(suppl 3):A128. Abstract.
55. Hutchinson M, Fazzini E. Cholinesterase inhibition in Parkinson's disease. J Neurol Neurosurg Psychiatry 1996;61:324- 326.
56. Parrott AC. Transdermal scopolamine: A review of its effects upon motion sickness, psychological performance, and physiological functioning. Aviation Space Environ Med 1989;60:1-9.
57. Sunderland T, Tariot P, Murphy DL, et al. Scopolamine challenges in Alzheimer's disease. Psychopharmacology 1985;87: 247-249.
58. Wesnes K, Warburton DM, Matz B. Effects of nicotine on stimulus sensitivity and response bias in a visual vigilance task. Neuropsychobiology 1983;9:41-44.
59. McKeith I, Del Ser T, Spano P, et al. Efficacy of rivastigmine in dementia with Lewy bodies: A randomised, double-blind placebo-controlled international study. Lancet 2000;356:2031-2036.